Research ExplorerPublicationsOutcomes of relapsed clinical stage I versus de novo metasta...

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database

Standard

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database. / Lauritsen, Jakob; Sauvé, Nicolas; Tryakin, Alexey; Jiang, Di Maria; Huddart, Robert; Heng, Daniel Y C; Terbuch, Angelika; Winquist, Eric; Chovanec, Michal; Hentrich, Marcus; Fankhauser, Christian D; Shamash, Jonathan; Del Muro, Xavier Garcia; Vaughn, David; Heidenreich, Axel; Sternberg, Cora N; Sweeney, Christopher; Necchi, Andrea; Bokemeyer, Carsten; Bandak, Mikkel; Jandari, Abolghassem; Collette, Laurence; Gillessen, Silke; Beyer, Joerg; Daugaard, Gedske.

In: BRIT J CANCER, Vol. 129, No. 11, 11.2023, p. 1759-1765.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lauritsen, J, Sauvé, N, Tryakin, A, Jiang, DM, Huddart, R, Heng, DYC, Terbuch, A, Winquist, E, Chovanec, M, Hentrich, M, Fankhauser, CD, Shamash, J, Del Muro, XG, Vaughn, D, Heidenreich, A, Sternberg, CN, Sweeney, C, Necchi, A, Bokemeyer, C, Bandak, M, Jandari, A, Collette, L, Gillessen, S, Beyer, J & Daugaard, G 2023, 'Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database', BRIT J CANCER, vol. 129, no. 11, pp. 1759-1765. https://doi.org/10.1038/s41416-023-02443-3

APA

Lauritsen, J., Sauvé, N., Tryakin, A., Jiang, D. M., Huddart, R., Heng, D. Y. C., Terbuch, A., Winquist, E., Chovanec, M., Hentrich, M., Fankhauser, C. D., Shamash, J., Del Muro, X. G., Vaughn, D., Heidenreich, A., Sternberg, C. N., Sweeney, C., Necchi, A., Bokemeyer, C., ... Daugaard, G. (2023). Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database. BRIT J CANCER, 129(11), 1759-1765. https://doi.org/10.1038/s41416-023-02443-3

Vancouver

Lauritsen J, Sauvé N, Tryakin A, Jiang DM, Huddart R, Heng DYC et al. Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database. BRIT J CANCER. 2023 Nov;129(11):1759-1765. https://doi.org/10.1038/s41416-023-02443-3

Bibtex

@article{f965710e75d1445aa298ba8750029e65,
title = "Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database",
abstract = "BACKGROUND: Active surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate.PATIENTS AND METHODS: In the IGCCCG Update database, we compared the outcomes of gonadal disseminated GCT relapsing from initial CSI to outcomes of patients with de novo metastatic GCT.RESULTS: A total of 1014 seminoma (Sem) [298 (29.4%) relapsed from CSI, 716 (70.6%) de novo] and 3103 non-seminoma (NSem) [626 (20.2%) relapsed from CSI, 2477 (79.8%) de novo] were identified. Among Sem, no statistically significant differences in PFS and OS were found between patients relapsing from CSI and de novo metastatic disease [5-year progression-free survival (5y-PFS) 87.6% versus 88.5%; 5-year overall survival (5y-OS) 93.2% versus 96.1%). Among NSem, PFS and OS were higher overall in relapsing CSI patients (5y-PFS 84.6% versus 80.0%; 5y-OS 93.3% versus 88.7%), but there were no differences within the same IGCCCG prognostic groups (HR = 0.89; 95% CI: 0.70-1.12). Relapses in the intermediate or poor prognostic groups occurred in 11/298 (4%) Sem and 112/626 (18%) NSem.CONCLUSION: Relapsing CSI GCT patients expect similar survival compared to de novo metastatic patients of the same ICCCCG prognostic group. Intermediate and poor prognosis relapses from initial CSI expose patients to unnecessary toxicity from more intensive treatments.",
author = "Jakob Lauritsen and Nicolas Sauv{\'e} and Alexey Tryakin and Jiang, {Di Maria} and Robert Huddart and Heng, {Daniel Y C} and Angelika Terbuch and Eric Winquist and Michal Chovanec and Marcus Hentrich and Fankhauser, {Christian D} and Jonathan Shamash and {Del Muro}, {Xavier Garcia} and David Vaughn and Axel Heidenreich and Sternberg, {Cora N} and Christopher Sweeney and Andrea Necchi and Carsten Bokemeyer and Mikkel Bandak and Abolghassem Jandari and Laurence Collette and Silke Gillessen and Joerg Beyer and Gedske Daugaard",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = nov,
doi = "10.1038/s41416-023-02443-3",
language = "English",
volume = "129",
pages = "1759--1765",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database

AU - Lauritsen, Jakob

AU - Sauvé, Nicolas

AU - Tryakin, Alexey

AU - Jiang, Di Maria

AU - Huddart, Robert

AU - Heng, Daniel Y C

AU - Terbuch, Angelika

AU - Winquist, Eric

AU - Chovanec, Michal

AU - Hentrich, Marcus

AU - Fankhauser, Christian D

AU - Shamash, Jonathan

AU - Del Muro, Xavier Garcia

AU - Vaughn, David

AU - Heidenreich, Axel

AU - Sternberg, Cora N

AU - Sweeney, Christopher

AU - Necchi, Andrea

AU - Bokemeyer, Carsten

AU - Bandak, Mikkel

AU - Jandari, Abolghassem

AU - Collette, Laurence

AU - Gillessen, Silke

AU - Beyer, Joerg

AU - Daugaard, Gedske

N1 - © 2023. The Author(s).

PY - 2023/11

Y1 - 2023/11

N2 - BACKGROUND: Active surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate.PATIENTS AND METHODS: In the IGCCCG Update database, we compared the outcomes of gonadal disseminated GCT relapsing from initial CSI to outcomes of patients with de novo metastatic GCT.RESULTS: A total of 1014 seminoma (Sem) [298 (29.4%) relapsed from CSI, 716 (70.6%) de novo] and 3103 non-seminoma (NSem) [626 (20.2%) relapsed from CSI, 2477 (79.8%) de novo] were identified. Among Sem, no statistically significant differences in PFS and OS were found between patients relapsing from CSI and de novo metastatic disease [5-year progression-free survival (5y-PFS) 87.6% versus 88.5%; 5-year overall survival (5y-OS) 93.2% versus 96.1%). Among NSem, PFS and OS were higher overall in relapsing CSI patients (5y-PFS 84.6% versus 80.0%; 5y-OS 93.3% versus 88.7%), but there were no differences within the same IGCCCG prognostic groups (HR = 0.89; 95% CI: 0.70-1.12). Relapses in the intermediate or poor prognostic groups occurred in 11/298 (4%) Sem and 112/626 (18%) NSem.CONCLUSION: Relapsing CSI GCT patients expect similar survival compared to de novo metastatic patients of the same ICCCCG prognostic group. Intermediate and poor prognosis relapses from initial CSI expose patients to unnecessary toxicity from more intensive treatments.

AB - BACKGROUND: Active surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate.PATIENTS AND METHODS: In the IGCCCG Update database, we compared the outcomes of gonadal disseminated GCT relapsing from initial CSI to outcomes of patients with de novo metastatic GCT.RESULTS: A total of 1014 seminoma (Sem) [298 (29.4%) relapsed from CSI, 716 (70.6%) de novo] and 3103 non-seminoma (NSem) [626 (20.2%) relapsed from CSI, 2477 (79.8%) de novo] were identified. Among Sem, no statistically significant differences in PFS and OS were found between patients relapsing from CSI and de novo metastatic disease [5-year progression-free survival (5y-PFS) 87.6% versus 88.5%; 5-year overall survival (5y-OS) 93.2% versus 96.1%). Among NSem, PFS and OS were higher overall in relapsing CSI patients (5y-PFS 84.6% versus 80.0%; 5y-OS 93.3% versus 88.7%), but there were no differences within the same IGCCCG prognostic groups (HR = 0.89; 95% CI: 0.70-1.12). Relapses in the intermediate or poor prognostic groups occurred in 11/298 (4%) Sem and 112/626 (18%) NSem.CONCLUSION: Relapsing CSI GCT patients expect similar survival compared to de novo metastatic patients of the same ICCCCG prognostic group. Intermediate and poor prognosis relapses from initial CSI expose patients to unnecessary toxicity from more intensive treatments.

U2 - 10.1038/s41416-023-02443-3

DO - 10.1038/s41416-023-02443-3

M3 - SCORING: Journal article

C2 - 37777577

VL - 129

SP - 1759

EP - 1765

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 11

ER -